Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Bone and Mineral Metabolism

25-04-2024 | Type 1 Diabetes | Invited Review

Vitamin D efficacy in type 1 and type 2 diabetes

Authors: Tetsuya Kawahara, Yosuke Okada, Yoshiya Tanaka

Published in: Journal of Bone and Mineral Metabolism

Login to get access

Abstract

It is well known that vitamin D has a profound effect on calcium and bone metabolism, but its influence on other organs (extraskeletal effect) has been proposed. Consistently, vitamin D deficiency is associated with an increased incidence of various diseases, including type 1 and type 2 diabetes, as reported by many observational studies. However, there has been no consensus on whether vitamin D deficiency is a causative factor in the incidence of diabetes mellitus. There have been no randomized controlled trials (RCTs) aimed at preventing the onset of type 1 diabetes with vitamin D intake. In addition, the results of RCTs evaluating the preventive effect of vitamin D supplementation on type 2 diabetes development have been inconsistent. The recent observational studies, randomized controlled trials, and meta-analyses are confirming that vitamin D or active vitamin D administration is effective in preventing the incident of type 1 and type 2 diabetes.
Literature
1.
Bouillon R, LeBoff MS, Neale RE (2023) Health effects of vitamin D supplementation: lessons learned from randomized controlled trials and mendelian randomization studies. J Bone Miner Res 38:1391–1403PubMedCrossRef
2.
Autier P, Boniol M, Pizot C, Mullie P (2014) Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol 2:76–89PubMedCrossRef
3.
Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, Gibson H, Gordon D, Copeland T, D’Agostino D, Friedenberg G, Ridge C, Bubes V, Giovannucci EL, Willett WC, Buring JE, Group VR (2019) Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med 380:33–44PubMedCrossRef
4.
Scragg R, Stewart AW, Waayer D, Lawes CMM, Toop L, Sluyter J, Murphy J, Khaw KT, Camargo CA Jr (2017) Effect of monthly high-dose vitamin D supplementation on cardiovascular disease in the vitamin D assessment study : a randomized clinical trial. JAMA Cardiol 2:608–616PubMedPubMedCentralCrossRef
5.
Wang H, Xia N, Yang Y, Peng DQ (2012) Influence of vitamin D supplementation on plasma lipid profiles: a meta-analysis of randomized controlled trials. Lipids Health Dis 11:42PubMedPubMedCentralCrossRef
6.
Sollid ST, Hutchinson MY, Fuskevag OM, Figenschau Y, Joakimsen RM, Schirmer H, Njolstad I, Svartberg J, Kamycheva E, Jorde R (2014) No effect of high-dose vitamin D supplementation on glycemic status or cardiovascular risk factors in subjects with prediabetes. Diabetes Care 37:2123–2131PubMedCrossRef
7.
Jorde R, Sneve M, Torjesen P, Figenschau Y (2010) No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year. J Intern Med 267:462–472PubMedCrossRef
8.
Martineau AR, Timms PM, Bothamley GH, Hanifa Y, Islam K et al (2011) High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 377:242–250PubMedPubMedCentralCrossRef
9.
Ganmaa D, Uyanga B, Zhou X, Gantsetseg G, Delgerekh B et al (2020) Vitamin D supplements for prevention of tuberculosis infection and disease. N Engl J Med 383:359–368PubMedPubMedCentralCrossRef
10.
Forno E, Bacharier LB, Phipatanakul W, Guilbert TW, Cabana MD, Ross K, Covar R, Gern JE, Rosser FJ, Blatter J, Durrani S, Han YY, Wisniewski SR, Celedon JC (2020) Effect of vitamin D3 supplementation on severe asthma exacerbations in children with asthma and low vitamin D levels: the VDKA randomized clinical trial. JAMA 324:752–760PubMedCrossRef
11.
Litonjua AA, Carey VJ, Laranjo N, Stubbs BJ, Mirzakhani H, O’Connor GT, Sandel M, Beigelman A, Bacharier LB, Zeiger RS, Schatz M, Hollis BW, Weiss ST (2020) Six-year follow-up of a trial of antenatal vitamin D for asthma reduction. N Engl J Med 382:525–533PubMedPubMedCentralCrossRef
12.
Bouillon R, Marcocci C, Carmeliet G, Bikle D, White JH, Dawson-Hughes B, Lips P, Munns CF, Lazaretti-Castro M, Giustina A, Bilezikian J (2019) Skeletal and extraskeletal actions of vitamin D: current evidence and outstanding questions. Endocr Rev 40:1109–1151PubMedCrossRef
13.
14.
Keum N, Chen QY, Lee DH, Manson JE, Giovannucci E (2022) Vitamin D supplementation and total cancer incidence and mortality by daily vs. infrequent large-bolus dosing strategies: a meta-analysis of randomised controlled trials. Br J Cancer 127:872–878PubMedPubMedCentralCrossRef
15.
Kuznia S, Zhu A, Akutsu T, Buring JE, Camargo CA Jr et al (2023) Efficacy of vitamin D(3) supplementation on cancer mortality: systematic review and individual patient data meta-analysis of randomised controlled trials. Ageing Res Rev 87:101923PubMedPubMedCentralCrossRef
16.
Rhead B, Baarnhielm M, Gianfrancesco M, Mok A, Shao X, Quach H, Shen L, Schaefer C, Link J, Gyllenberg A, Hedstrom AK, Olsson T, Hillert J, Kockum I, Glymour MM, Alfredsson L, Barcellos LF (2016) Mendelian randomization shows a causal effect of low vitamin D on multiple sclerosis risk. Neurol Genet 2:e97PubMedPubMedCentralCrossRef
17.
Gianfrancesco MA, Stridh P, Rhead B, Shao X, Xu E et al (2017) Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS. Neurology 88:1623–1629PubMedPubMedCentralCrossRef
18.
Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF et al (2017) Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ 356:i6583PubMedPubMedCentralCrossRef
19.
Jolliffe DA, Camargo CA Jr, Sluyter JD, Aglipay M, Aloia JF et al (2021) Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials. Lancet Diabetes Endocrinol 9:276–292PubMedCrossRef
20.
Hahn J, Cook NR, Alexander EK, Friedman S, Walter J, Bubes V, Kotler G, Lee IM, Manson JE, Costenbader KH (2022) Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ 376:e066452PubMedPubMedCentralCrossRef
21.
Wu B, Fu Z, Wang X, Zhou P, Yang Q, Jiang Y, Zhu D (2022) A narrative review of diabetic bone disease: characteristics, pathogenesis, and treatment. Front Endocrinol (Lausanne) 13:1052592PubMedCrossRef
22.
Cavati G, Pirrotta F, Merlotti D, Ceccarelli E, Calabrese M, Gennari L, Mingiano C (2023) Role of advanced glycation end-products and oxidative stress in type-2-diabetes-induced bone fragility and implications on fracture risk stratification. Antioxidants (Basel) 12:928PubMedCrossRef
23.
Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G (2007) Endocrine regulation of energy metabolism by the skeleton. Cell 130:456–469PubMedPubMedCentralCrossRef
24.
Kawahara T, Suzuki G, Mizuno S, Inazu T, Kasagi F, Kawahara C, Okada Y, Tanaka Y (2022) Effect of active vitamin D treatment on development of type 2 diabetes: DPVD randomised controlled trial in Japanese population. BMJ 377:e066222PubMedPubMedCentralCrossRef
25.
Papadimitropoulos E, Wells G, Shea B, Gillespie W, Weaver B, Zytaruk N, Cranney A, Adachi J, Tugwell P, Josse R, Greenwood C, Guyatt G, Osteoporosis Methodology G, The Osteoporosis Research Advisory G (2002) Meta-analyses of therapies for postmenopausal osteoporosis. VIII: meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 23:560–569PubMedCrossRef
26.
Rosendahl-Riise H, Spielau U, Ranhoff AH, Gudbrandsen OA, Dierkes J (2017) Vitamin D supplementation and its influence on muscle strength and mobility in community-dwelling older persons: a systematic review and meta-analysis. J Hum Nutr Diet 30:3–15PubMedCrossRef
27.
Ringe JD (2020) Plain vitamin D or active vitamin D in the treatment of osteoporosis: where do we stand today? Arch Osteoporos 15:182PubMedCrossRef
28.
(1999) Vitamin D supplement in early childhood and risk for type I (insulin-dependent) diabetes mellitus. The EURODIAB Substudy 2 Study Group. Diabetologia 42:51–54
29.
Stene LC, Ulriksen J, Magnus P, Joner G (2000) Use of cod liver oil during pregnancy associated with lower risk of type I diabetes in the offspring. Diabetologia 43:1093–1098PubMedCrossRef
30.
Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM (2001) Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 358:1500–1503PubMedCrossRef
31.
Stene LC, Joner G, Norwegian Childhood Diabetes Study G (2003) Use of cod liver oil during the first year of life is associated with lower risk of childhood-onset type 1 diabetes: a large, population-based, case-control study. Am J Clin Nutr 78:1128–1134PubMedCrossRef
32.
Visalli N, Sebastiani L, Adorisio E, Conte A, De Cicco AL, D’Elia R, Manfrini S, Pozzilli P, Group I (2003) Environmental risk factors for type 1 diabetes in Rome and province. Archiv Dis Childh 88:695–698CrossRef
33.
Tenconi MT, Devoti G, Comelli M, Pinon M, Capocchiano A, Calcaterra V, Pretti G, Pavia TDMRG (2007) Major childhood infectious diseases and other determinants associated with type 1 diabetes: a case-control study. Acta Diabetol 44:14–19PubMedCrossRef
34.
Ahadi M, Tabatabaeiyan M, Moazzami K (2011) Association between environmental factors and risk of type 1 diabetes—a case–control study. Endokrynol Pol 62:134–137PubMed
35.
Simpson M, Brady H, Yin X, Seifert J, Barriga K, Hoffman M, Bugawan T, Baron AE, Sokol RJ, Eisenbarth G, Erlich H, Rewers M, Norris JM (2011) No association of vitamin D intake or 25-hydroxyvitamin D levels in childhood with risk of islet autoimmunity and type 1 diabetes: the diabetes autoimmunity study in the young (DAISY). Diabetologia 54:2779–2788PubMedPubMedCentralCrossRef
36.
Davidson MB, Duran P, Lee ML, Friedman TC (2013) High-dose vitamin D supplementation in people with prediabetes and hypovitaminosis D. Diabetes Care 36:260–266PubMedPubMedCentralCrossRef
37.
Barengolts E, Manickam B, Eisenberg Y, Akbar A, Kukreja S, Ciubotaru I (2015) Effect of high-dose vitamin D repletion on glycemic control in African–American males with prediabetes and hypovitaminosis D. Endocr Pract 21:604–612PubMedPubMedCentralCrossRef
38.
Kuchay MS, Laway BA, Bashir MI, Wani AI, Misgar RA, Shah ZA (2015) Effect of vitamin D supplementation on glycemic parameters and progression of prediabetes to diabetes: a 1-year, open-label randomized study. Indian J Endocrinol Metab 19:387–392PubMedPubMedCentralCrossRef
39.
Jorde R, Sollid ST, Svartberg J, Schirmer H, Joakimsen RM, Njolstad I, Fuskevag OM, Figenschau Y, Hutchinson MY (2016) Vitamin D 20,000 IU per week for five years does not prevent progression from prediabetes to diabetes. J Clin Endocrinol Metab 101:1647–1655PubMedCrossRef
40.
Niroomand M, Fotouhi A, Irannejad N, Hosseinpanah F (2019) Does high-dose vitamin D supplementation impact insulin resistance and risk of development of diabetes in patients with pre-diabetes? A double-blind randomized clinical trial. Diabetes Res Clin Pract 148:1–9PubMedCrossRef
41.
Pittas AG, Dawson-Hughes B, Sheehan P, Ware JH, Knowler WC et al (2019) Vitamin D supplementation and prevention of type 2 diabetes. N Engl J Med 381:520–530PubMedPubMedCentralCrossRef
42.
Zhang Y, Tan H, Tang J, Li J, Chong W, Hai Y, Feng Y, Lunsford LD, Xu P, Jia D, Fang F (2020) Effects of vitamin D supplementation on prevention of type 2 diabetes in patients with prediabetes: a systematic review and meta-analysis. Diabetes Care 43:1650–1658PubMedCrossRef
43.
Barbarawi M, Zayed Y, Barbarawi O, Bala A, Alabdouh A, Gakhal I, Rizk F, Alkasasbeh M, Bachuwa G, Manson JE (2020) Effect of vitamin D supplementation on the incidence of diabetes mellitus. J Clin Endocrinol Metab 105:2857–2868CrossRef
44.
Pittas AG, Kawahara T, Jorde R, Dawson-Hughes B, Balk EM (2023) Vitamin D and risk for type 2 diabetes in people with prediabetes. Ann Intern Med 176:eL230202PubMedCrossRef
45.
Lee S, Clark SA, Gill RK, Christakos S (1994) 1,25-Dihydroxyvitamin D3 and pancreatic beta-cell function: vitamin D receptors, gene expression, and insulin secretion. Endocrinology 134:1602–1610PubMedCrossRef
46.
Adorini L (2003) Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting autoimmune diabetes. Ann N Y Acad Sci 987:258–261PubMedCrossRef
47.
Mathieu C, van Etten E, Decallonne B, Guilietti A, Gysemans C, Bouillon R, Overbergh L (2004) Vitamin D and 1,25-dihydroxyvitamin D3 as modulators in the immune system. J Steroid Biochem Mol Biol 89–90:449–452PubMedCrossRef
48.
Mathieu C, Adorini L (2002) The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med 8:174–179PubMedCrossRef
49.
van Etten E, Decallonne B, Bouillon R, Mathieu C (2004) NOD bone marrow-derived dendritic cells are modulated by analogs of 1,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol 89–90:457–459PubMedCrossRef
50.
Griffin MD, Lutz WH, Phan VA, Bachman LA, McKean DJ, Kumar R (2000) Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem Biophys Res Commun 270:701–708PubMedCrossRef
51.
Penna G, Adorini L (2000) 1 Alpha, 25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 164:2405–2411PubMedCrossRef
52.
Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ, Kumar R (2001) Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci USA 98:6800–6805PubMedPubMedCentralCrossRef
53.
Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O’Garra A (2001) 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 167:4974–4980PubMedCrossRef
54.
Gregori S, Giarratana N, Smiroldo S, Uskokovic M, Adorini L (2002) A 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 51:1367–1374PubMedCrossRef
55.
D’Ambrosio D, Cippitelli M, Cocciolo MG, Mazzeo D, Di Lucia P, Lang R, Sinigaglia F, Panina-Bordignon P (1998) Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Investig 101:252–262PubMedPubMedCentralCrossRef
56.
Sandler S, Buschard K, Bendtzen K (1994) Effects of 1,25-dihydroxyvitamin D3 and the analogues MC903 and KH1060 on interleukin-1 beta-induced inhibition of rat pancreatic islet beta-cell function in vitro. Immunol Lett 41:73–77PubMedCrossRef
57.
Hahn HJ, Kuttler B, Mathieu C, Bouillon R (1997) 1,25-Dihydroxyvitamin D3 reduces MHC antigen expression on pancreatic beta-cells in vitro. Transplant Proc 29:2156–2157PubMedCrossRef
58.
Riachy R, Vandewalle B, Kerr Conte J, Moerman E, Sacchetti P, Lukowiak B, Gmyr V, Bouckenooghe T, Dubois M, Pattou F (2002) 1,25-Dihydroxyvitamin D3 protects RINm5F and human islet cells against cytokine-induced apoptosis: implication of the antiapoptotic protein A20. Endocrinology 143:4809–4819PubMedCrossRef
59.
Ponsonby AL, McMichael A, van der Mei I (2002) Ultraviolet radiation and autoimmune disease: insights from epidemiological research. Toxicology 181–182:71–78PubMedCrossRef
60.
61.
Cooper JD, Smyth DJ, Walker NM, Stevens H, Burren OS, Wallace C, Greissl C, Ramos-Lopez E, Hypponen E, Dunger DB, Spector TD, Ouwehand WH, Wang TJ, Badenhoop K, Todd JA (2011) Inherited variation in vitamin D genes is associated with predisposition to autoimmune disease type 1 diabetes. Diabetes 60:1624–1631PubMedPubMedCentralCrossRef
62.
Pozzilli P, Manfrini S, Crino A, Picardi A, Leomanni C, Cherubini V, Valente L, Khazrai M, Visalli N, Group I (2005) Low levels of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 in patients with newly diagnosed type 1 diabetes. Horm Metab Res 37:680–683PubMedCrossRef
63.
Mathieu C, Gysemans C, Giulietti A, Bouillon R (2005) Vitamin D and diabetes. Diabetologia 48:1247–1257PubMedCrossRef
64.
Zipitis CS, Akobeng AK (2008) Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch Dis Child 93:512–517PubMedCrossRef
65.
Dong JY, Zhang WG, Chen JJ, Zhang ZL, Han SF, Qin LQ (2013) Vitamin D intake and risk of type 1 diabetes: a meta-analysis of observational studies. Nutrients 5:3551–3562PubMedPubMedCentralCrossRef
66.
Pitocco D, Crino A, Di Stasio E, Manfrini S, Guglielmi C, Spera S, Anguissola GB, Visalli N, Suraci C, Matteoli MC, Patera IP, Cavallo MG, Bizzarri C, Pozzilli P, Group I (2006) The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset type 1 diabetes (IMDIAB XI). Diabet Med J Br Diabet Assoc 23:920–923CrossRef
67.
Bizzarri C, Pitocco D, Napoli N, Di Stasio E, Maggi D, Manfrini S, Suraci C, Cavallo MG, Cappa M, Ghirlanda G, Pozzilli P, Group I (2010) No protective effect of calcitriol on beta-cell function in recent-onset type 1 diabetes: the IMDIAB XIII trial. Diabetes Care 33:1962–1963PubMedPubMedCentralCrossRef
68.
Walter M, Kaupper T, Adler K, Foersch J, Bonifacio E, Ziegler AG (2010) No effect of the 1alpha,25-dihydroxyvitamin D3 on beta-cell residual function and insulin requirement in adults with new-onset type 1 diabetes. Diabetes Care 33:1443–1448PubMedPubMedCentralCrossRef
69.
Gabbay MA, Sato MN, Finazzo C, Duarte AJ, Dib SA (2012) Effect of cholecalciferol as adjunctive therapy with insulin on protective immunologic profile and decline of residual beta-cell function in new-onset type 1 diabetes mellitus. Arch Pediatr Adolesc Med 166:601–607PubMedCrossRef
70.
d’Emden MC, Dunlop M, Larkins RG, Wark JD (1989) The in vitro effect of 1 alpha,25-dihydroxyvitamin D3 on insulin production by neonatal rat islets. Biochem Biophys Res Commun 164:413–418PubMedCrossRef
71.
Sooy K, Schermerhorn T, Noda M, Surana M, Rhoten WB, Meyer M, Fleischer N, Sharp GW, Christakos S (1999) Calbindin-D(28k) controls [Ca(2+)](i) and insulin release. Evidence obtained from calbindin-d(28k) knockout mice and beta cell lines. J Biol Chem 274:34343–34349PubMedCrossRef
72.
Rabinovitch A, Suarez-Pinzon WL, Sooy K, Strynadka K, Christakos S (2001) Expression of calbindin-D(28k) in a pancreatic islet beta-cell line protects against cytokine-induced apoptosis and necrosis. Endocrinology 142:3649–3655PubMedCrossRef
73.
Norman AW, Frankel JB, Heldt AM, Grodsky GM (1980) Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 209:823–825PubMedCrossRef
74.
Cade C, Norman AW (1986) Vitamin D3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. Endocrinology 119:84–90PubMedCrossRef
75.
76.
Nyomba BL, Bouillon R, De Moor P (1984) Influence of vitamin D status on insulin secretion and glucose tolerance in the rabbit. Endocrinology 115:191–197PubMedCrossRef
77.
Song Y, Wang L, Pittas AG, Del Gobbo LC, Zhang C, Manson JE, Hu FB (2013) Blood 25-hydroxy vitamin D levels and incident type 2 diabetes: a meta-analysis of prospective studies. Diabetes Care 36:1422–1428PubMedPubMedCentralCrossRef
78.
Kayaniyil S, Vieth R, Retnakaran R, Knight JA, Qi Y, Gerstein HC, Perkins BA, Harris SB, Zinman B, Hanley AJ (2010) Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care 33:1379–1381PubMedPubMedCentralCrossRef
79.
Knekt P, Laaksonen M, Mattila C, Harkanen T, Marniemi J, Heliovaara M, Rissanen H, Montonen J, Reunanen A (2008) Serum vitamin D and subsequent occurrence of type 2 diabetes. Epidemiology 19:666–671PubMedCrossRef
80.
Kaga H, Tamura Y, Someya Y, Naito H, Tabata H, Kakehi S, Yamasaki N, Sato M, Kadowaki S, Suzuki R, Sugimoto D, Kawamori R, Watada H (2022) Prediabetes is an independent risk factor for sarcopenia in older men, but not in older women: the Bunkyo Health Study. J Cachexia Sarcopenia Muscle 13:2835–2842PubMedPubMedCentralCrossRef
81.
Miyamoto H, Kawakami D, Hanafusa N, Nakanishi T, Miyasaka M, Furutani Y, Ikeda Y, Ito K, Kato T, Yokoyama K, Arakawa S, Saito M, Furusho T, Matsuura T, Ochi S (2023) Determination of a serum 25-hydroxyvitamin D reference ranges in Japanese adults using fully automated liquid chromatography-tandem mass spectrometry. J Nutr 153:1253–1264PubMedCrossRef
82.
Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes M, Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, Ito C, Inagaki N, Iwamoto Y, Kasuga M, Hanafusa T, Haneda M, Ueki K (2010) Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig 1:212–228CrossRef
83.
Rifai N (2018) Tietz textbook of clinical chemistry and molecular diagnostics. Elsevier, St.Louis, Missouri
84.
Gallagher JC, Rosen CJ (2023) Vitamin D: 100 years of discoveries, yet controversy continues. Lancet Diabetes Endocrinol 11:362–374PubMedCrossRef
Metadata
Title
Vitamin D efficacy in type 1 and type 2 diabetes
Authors
Tetsuya Kawahara
Yosuke Okada
Yoshiya Tanaka
Publication date
25-04-2024
Publisher
Springer Nature Singapore
Published in
Journal of Bone and Mineral Metabolism
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-024-01509-3
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits